AAAP:NSD-Advanced Accelerator Applications S.A (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 3.75

Change

0.00 (0.00)%

Market Cap

USD 3.61B

Volume

6.00K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Advanced Accelerator Applications S.A. develops, produces, and commercializes radiolabeled pharmaceuticals and diagnostic nuclear medicines in France and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of oncology through assessing glucose metabolism; DOPAVIEW, a PET tracer for diagnostic use with applications in neurology and oncology sectors; and FluoroChol, a PET tracer for detecting metastasis of prostate cancer and hepatocellular carcinoma. The company also offers single-photon emission computed tomography (SPECT) products comprising Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate, a cardiac imaging agent for myocardial exploration, localization of parathyroid tissue, and breast cancer diagnosis; and Leukokit, a single-use medical device to carry out separation and labeling of autologous leukocytes. In addition, it offers NETSPOT, a kit for the preparation of gallium Ga 68 dotatate injection for the localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients using PET; SomaKit TOC, a kit for radiopharmaceutical preparation of gallium edotreotide solution; and Annexin V-128, a SPECT radiopharmaceutical product candidate for the imaging of apoptotic and necrotic lesions. Its products that are in clinical development comprise Lutathera, a Lu-177 labeled somatostatin analogue peptide that has been approved for the treatment of neuro endocrine tumors; PSMA-R2, a selective PSMA-targeted ligand for prostate cancer; and NeoBOMB1, an antagonist bombesin analogue targeting GRPR-expressing malignancies. The company was founded in 2002 and is headquartered in Saint Genis Pouilly, France. As of January 31, 2018, Advanced Accelerator Applications S.A. operates as a subsidiary of Novartis Groupe France S.A.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-03 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

+0.70 (+0.86%)

USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

-0.03 (-3.33%)

USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

USD38,513.36B N/A N/A

ETFs Containing AAAP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -95.41% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.41% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 37.88% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.88% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 62.34% N/A N/A N/A N/A
Risk Adjusted Return 60.76% N/A N/A N/A N/A
Market Capitalization 3.61B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.04 N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -7.53% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 4.11% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.60 N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.66 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike